Optomed Oyj Class A · OMXHEX:OPTOMED
Optomed Oyj Class A — Investor Presentation (November 2022)
18 slides from Optomed Oyj Class A's investor presentation, November 2022
Slide 1: Optomed in Brief
Optomed IR presentation November 2022 Optomed in Brief
Slide 2: Global megatrends increasing demand
Global megatrends increasing demand Aging population Diabetes growing AI Prevalence of serious eye Diabetic Retinopathy (causing Technological advances in diseases (causing vision vision loss) affects ~35% of all artificial intelligence enable loss) increase strongly diabetics but can be prevented b
Slide 3: The prevalence of eye diseases is expected to increase rapidly
The prevalence of eye diseases is expected to increase rapidly which will again increase the need for screening Diabetic retinopathy Glaucoma AMD 463 M at risk. 895 M over 60 years old at risk. 604 M over 65 years old at risk. The leading cause of vision loss in adults. Prevalence increases by age.
Slide 4: Globally, there are only <250 000 eye doctors and the geographical dispersion is high
Globally, there is only <250 000 eye doctors and the geographical dispersion is high Resnikoff S, Lansingh VC, Washburn L, et al British Journal of Ophthalmology 2020;104:588-592. Traditional screening methods are not sufficiently scalable to address the need
Slide 5: Transition from traditional desktop cameras to AI integrated handheld cameras has started
Transition from traditional desktop cameras to AI integrated handheld cameras has started Traditional equipment Optomed’s handheld camera… …together with AI • Large initial investments • Cost efficient • Saves eye doctor • Space constrains • For the use of all healthcare resources and lowers • For p
Slide 6: AI to increase the pace of transition towards primary care especially in the US
AI to increase the pace of transition towards primary care especially in the US The number of primary care doctors is significantly higher than the number of eye doctors (USA 246 0001 vs. 24 0002) Primary Care The reimbursement code for the screening of diabetic retinopathy using artificial intellig
Slide 7: Optomed is the leading handheld fundus camera manufacturer
Optomed is the leading handheld fundus camera manufacturer Established 2004, HQ and product development in Oulu, Finland Revenue 15 MEUR (2021) Over 60 distributors in 50 countries; several OEM partners Several AI partnerships e.g.. AEYE Health Ltd, Eyenuk Inc, EyRIS Pte. Ltd. Office Outsourced manu
Slide 8: Optomed's current Product Portfolio
Optomed’s current Product Portfolio Volk Haag-Streit Optomed Smartscope Picture Plus Topcon Zeiss Optomed Optomed Optomed Fundus Aurora IQ PRO & Prestige Signal Visuscout Module 300 Polaris Halo E-Safe Optomed Avenue Avenue Screen Avenue Archive Avenue Avenue AI Avenue Sync Optomed Screen is a workf
Slide 9: Clinical Trial
Clinical Trial • 91.9% sensitivity • 93.6% specificity • 99+% imageability • Only a single image per eye Optomed and AEYE Health are seeking FDA clearance for the solution. The companies expect that they are able to address the latest feedback from the FDA in the coming months after which they will
Slide 10: New Recurring Revenue Model in the US
New Recurring Revenue Model in the US Complete Solution Recurring Revenue Model Customer Benefits From product sales to complete Solution leased, not screening solutions with diagnosis No initial investments sold – enables Only monthly rental fee recurring revenue Excellent clinical results, Fixed a
Slide 11: Optomed's Artificial Intelligence
Optomed’s Artificial Intelligence 2022 Near-term future Future opportunities Eye-diseases Expansion to other diseases Preventive health-check in primary care Diabetic Retinopathy, age- All eye disorders, neurological Eye disease, neurological disorders, related macular degeneration disorders, kidney
Slide 12: Optomed's growth strategy – status update
Optomed’s growth strategy – status update Growth in existing markets Expansion into Focus on bringing new products and entering geographical new new customer segments and solutions to the market markets • Building of sales and distribution • Aurora IQ, the first fundus camera that • Optomed USA esta
Slide 13: Optomed Plc. contact details
Optomed Plc. Yrttipellontie 1, 90230 Oulu, Finland Tel: +358 20 741 3380 • investors@optomed.com www.optomed.com
Slide 14: Q3/2022 Key Figures
Q3/2022 Key Figures Q3/2022 Q3/2021 Change Revenue 3,700 3,342 10.7% Gross profit 1) 2,967 2,250 31.8% Gross margin 2) 80.2% 67.3% EBITDA 145 -337 143.1% EBITDA margin 3.9% -10.1% Net profit / loss -1,377 -833 -65.3% Earnings per share -0.10 -0.06 -56.2% Cash flow from operating activities -504 -764
Slide 15: Balance Sheet
Balance Sheet 30 September 2022 30 September 2021 • Equity ratio of 63.3 (62.7) ASSETS percent Goodwill 4,256 4,256 Development costs 6,287 5,735 Other intangible assets • Total borrowings of EUR 5.4 1,220 1,441 Total intangible assets 12,683 12,528 (6.8) million Total tangible assets 1,867 1,347 To
Slide 16: Cash Flow Q3/2022
Cash Flow Q3/2022 Q3 2022 Q3 2021 • Cash flow from operating Loss for the financial year -1,377 -833 activities amounted to EUR -504 Cash flows before change -565 -207 in net working capital (-764) thousand Change in net working capital 116 -540 • Comparison period net Cash flows before finance item
Slide 17: Cash Flow 1-9/2022
Cash Flow 1-9/2022 1-9/2022 1-9/2022 Loss for the financial year -4,075 -2,313 Cash flows before change in net working capital -2,204 -673 Change in net working capital 243 -1,701 Cash flows before finance items -1,962 -2,373 Cash flows from finance items -132 -77 Net cash from operating activities
Slide 18: 1-12/2021 Financial highlights (KEUR)
1-12/2021 Financial highlights (KEUR) 1-12/2021 1-12/2020 Change Revenue 14,850 13,011 14.1% Gross profit 1) 10,558 8,955 17.9% Gross margin 2) 71.1% 68.8% +230 bps Adjusted EBITDA -2,002 -733 -173.2% Adjusted EBITDA margin -13.5% -5.6% -790 bps Net profit/ loss -4,249 -3,177 -33.8% Earnings per sha